Advanced search
Publication Cover
Molecular and Cellular Biology Volume 26, 2006 - Issue 16
Submit an article Journal homepage
43
Views
157
CrossRef citations to date
0
Altmetric
Article

Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

Ian J. Griswold1 Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute;3 Howard Hughes Medical Institute, 3181 S.W. Sam Jackson Park Rd., Portland, Oregon97239-3098
,
Mary MacPartlin1 Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute
,
Thomas Bumm1 Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute
,
Valerie L. Goss4 Cell Signaling Technology, Inc., 166B Cummings Center, Beverly, Massachusetts01915
,
Thomas O'Hare1 Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute;3 Howard Hughes Medical Institute, 3181 S.W. Sam Jackson Park Rd., Portland, Oregon97239-3098
,
Kimberly A. Lee4 Cell Signaling Technology, Inc., 166B Cummings Center, Beverly, Massachusetts01915
,
Amie S. Corbin1 Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute;3 Howard Hughes Medical Institute, 3181 S.W. Sam Jackson Park Rd., Portland, Oregon97239-3098
,
Eric P. Stoffregen1 Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute
,
Caitlyn Smith1 Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute
,
Kara Johnson1 Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute
,
Erika M. Moseson1 Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute
,
Lisa J. Wood2 Oregon Health and Science University School of Nursing
,
Roberto D. Polakiewicz4 Cell Signaling Technology, Inc., 166B Cummings Center, Beverly, Massachusetts01915
,
Brian J. Druker1 Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute;3 Howard Hughes Medical Institute, 3181 S.W. Sam Jackson Park Rd., Portland, Oregon97239-3098
&
Michael W. Deininger1 Center for Hematologic Malignancies, Oregon Health and Science University Cancer InstituteCorrespondence[email protected]
 show all
Pages 6082-6093 | Received 14 Nov 2005, Accepted 08 May 2006, Published online: 27 Mar 2023

Citations (157)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Lulu Wang, Li Li, Rongrong Chen, Xianbo Huang & Xiujin Ye. (2021) Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients. Cancer Management and Research 13, pages 4987-5000.
Read now
Neel H. Shah, Jeanine F. Amacher, Laura M. Nocka & John Kuriyan. (2018) The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases. Critical Reviews in Biochemistry and Molecular Biology 53:5, pages 535-563.
Read now
Afia Muhammad Akram, Zafar Iqbal, Tanveer Akhtar, Ahmed Mukhtar Khalid, Muhammad Farooq Sabar, Mahmood Hussain Qazi, Zeba Aziz, Nadia Sajid, Aamer Aleem, Mahmood Rasool, Muhammad Asif, Saleh Aloraibi, Khaled Aljamaan & Mudassar Iqbal. (2017) Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression. Cancer Biology & Therapy 18:4, pages 214-221.
Read now
Byung Woong Ko, Jeongsu Han, Jun Young Heo, Yunseon Jang, Soo Jeong Kim, Jungim Kim, Min Joung Lee, Min Jeong Ryu, Ik Chan Song, Young Suk Jo & Gi Ryang Kweon. (2016) Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production. Leukemia & Lymphoma 57:9, pages 2180-2188.
Read now
Jianli Gong, Yongneng Yao, Pingbo Zhang, Barath Udayasuryan, Elena V. Komissarova, Ju Chen, Sivaraj Sivaramakrishnan, Jennifer E. Van Eyk & Susan F. Steinberg. (2015) The C2 Domain and Altered ATP-Binding Loop Phosphorylation at Ser359 Mediate the Redox-Dependent Increase in Protein Kinase C-δ Activity. Molecular and Cellular Biology 35:10, pages 1727-1740.
Read now
Rina Barouch-Bentov & Karsten Sauer. (2011) Mechanisms of drug resistance in kinases. Expert Opinion on Investigational Drugs 20:2, pages 153-208.
Read now
Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew & Francis Giles. (2009) Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Design, Development and Therapy 3, pages 89-101.
Read now
Martin Henkes, Heiko van der Kuip & Walter E Aulitzky. (2008) Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™). Therapeutics and Clinical Risk Management 4:1, pages 163-187.
Read now
D. M. Ross & T. P. Hughes. (2008) Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders. Pathology 40:3, pages 231-246.
Read now
Peter Valent. (2007) Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. Biologics: Targets and Therapy 1:4, pages 433-448.
Read now

Articles from other publishers (147)

Susan Branford & Jane F. Apperley. (2022) Measurable residual disease in chronic myeloid leukemia. Haematologica 107:12, pages 2794-2809.
Crossref
Gustavo P. Amarante-Mendes, Aamir Rana, Tarcila Santos Datoguia, Nelson Hamerschlak & Gabriela Brumatti. (2022) BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia. Pharmaceutics 14:1, pages 215.
Crossref
Emiko Kinoshita-Kikuta, Eiji Kinoshita & Tohru Koike. (2022) Characterization of phosphorylation status and kinase activity of Src family kinases expressed in cell-based and cell-free protein expression systemsさまざまなタンパク質合成系で作成したSrcファミリーチロシンキナーゼのリン酸化状態と活性. Electrophoresis Letters 66:2, pages 71-79.
Crossref
Constance Baer, Manja Meggendorfer, Claudia Haferlach, Wolfgang Kern & Torsten Haferlach. (2021) Detection of <I>ABL1</I> kinase domain mutations in therapy-naïve <I>BCR-ABL1</I>-positive acute lymphoblastic leukemia. Haematologica 107:2, pages 562-563.
Crossref
Nikola Curik, Vaclava Polivkova, Pavel Burda, Jitka Koblihova, Adam Laznicka, Tomas Kalina, Veronika Kanderova, Jana Brezinova, Sarka Ransdorfova, Dominika Karasova, Katerina Rejlova, Marina Bakardjieva, Daniela Kuzilkova, David Kundrat, Jana Linhartova, Hana Klamova, Cyril Salek, Pavel Klener, Ondrej Hrusak & Katerina Machova Polakova. (2021) Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining. Frontiers in Oncology 11.
Crossref
Michele Massimino, Elena Tirrò, Stefania Stella, Livia Manzella, Maria Stella Pennisi, Chiara Romano, Silvia Rita Vitale, Adriana Puma, Cristina Tomarchio, Sandra Di Gregorio, Agostino Antolino, Francesco Di Raimondo & Paolo Vigneri. (2021) Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts. Frontiers in Pharmacology 12.
Crossref
Emiko Kinoshita-Kikuta, Momoka Yoshimoto, Marina Yano, Eiji Kinoshita & Tohru Koike. (2021) An assay of human tyrosine protein kinase ABL activity using an Escherichia coli protein expression system . BioTechniques 70:4, pages 209-217.
Crossref
Hala Elsir Khair, Abozer Yousif Elderdery, Bakri Yousef Nour, Hadeil Mohamed Elamin Idris, Gamila Ali Attaelmanan, Babker Ahmed Mohamed & Hisham Ali Waggiallah. (2021) BCR-ABL Kinase Domain mutations - E255K, Y253 H and M351T among Sudanese population with CML. Pharmacophore 12:4, pages 112-118.
Crossref
Oliver Parting, Samantha Langer, Maja Kim Kuepper, Caroline Wessling, Shaoguang Li, Till Braunschweig, Nicolas Chatain, Tiago Maié, Ivan G. Costa, Martina Crysandt, Michael Huber, Tim H. Brümmendorf, Steffen Koschmieder & Mirle Schemionek. (2020) Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia. Leukemia 34:10, pages 2635-2647.
Crossref
Marc Hoemberger, Warintra Pitsawong & Dorothee Kern. (2020) Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase. Proceedings of the National Academy of Sciences 117:32, pages 19221-19227.
Crossref
Rahul Kumar, Raquel S. Pereira, Costanza Zanetti, Valentina R. Minciacchi, Maximilian Merten, Melanie Meister, Julian Niemann, Marina S. Dietz, Nina Rüssel, Frank Schnütgen, Minori Tamai, Koshi Akahane, Takeshi Inukai, Thomas Oellerich, Hans Michael Kvasnicka, Heike Pfeifer, Franck E. Nicolini, Mike Heilemann, Richard A. Van Etten & Daniela S. Krause. (2020) Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia. Leukemia 34:8, pages 2087-2101.
Crossref
Simona Soverini, Francesco Albano, Renato Bassan, Francesco Fabbiano, Felicetto Ferrara, Robin Foà, Attilio Olivieri, Alessandro Rambaldi, Giuseppe Rossi, Simona Sica, Giorgina Specchia, Adriano Venditti, Giovanni Barosi & Fabrizio Pane. (2020) Next‐generation sequencing for BCR‐ABL1 kinase domain mutations in adult patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A position paper . Cancer Medicine 9:9, pages 2960-2970.
Crossref
Mathias Schneeweiss-Gleixner, Konstantin Byrgazov, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Chantal Blanche Lucini, Susanne Herndlhofer, Sandra Preuner, Klara Obrova, Petra Pusic, Nadine Witzeneder, Georg Greiner, Gregor Hoermann, Wolfgang R. Sperr, Thomas Lion, Michael Deininger, Peter Valent & Karoline V. Gleixner. (2019) CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. EBioMedicine 50, pages 111-121.
Crossref
Irina Cezara Vacarean-Trandafir, Iuliu Cristian Ivanov, Loredana Mihaiela Dragos, Angela Smaranda Dascalescu, Amalia Andrea Titieanu & Dumitru Cojocaru. (2019) ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance. Molecular Biology Reports 46:4, pages 3747-3754.
Crossref
Hea-Lyun Yoo, Soo-Hyun Kim, Soo-Young Choi, Sung-Eun Lee & Dong-Wook Kim. (2019) Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis on the Basis of European LeukemiaNet Recommendations in Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 19:7, pages 406-412.e1.
Crossref
Panagiota S. Georgoulia, Guido Todde, Sinisa Bjelic & Ran Friedman. (2019) The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia. Biochimica et Biophysica Acta (BBA) - General Subjects 1863:4, pages 732-741.
Crossref
Karoline V. Gleixner, Irina Sadovnik, Mathias Schneeweiss, Gregor Eisenwort, Konstantin Byrgazov, Gabriele Stefanzl, Daniela Berger, Harald Herrmann, Emir Hadzijusufovic, Thomas Lion & Peter Valent. (2019) A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML. Leukemia Research 78, pages 36-44.
Crossref
Jee-Eun Jang, Hwang-Phill Kim, Sae-Won Han, Hoon Jang, Si-Hyun Lee, Sang-Hyun Song, Duhee Bang & Tae-You Kim. (2019) NFATC3–PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines. Cancer Research and Treatment 51:1, pages 391-401.
Crossref
Ki-Hoon Kang, Soo-Hyun Kim, Soo-Young Choi, Hae-Lyun Yoo, Mi-Young Lee, Hye-Young Song, Kyung-Mi Kee, Ji-Hyung Suh, Seon-Young Yang, Eun-Jung Jang, Sung-Eun Lee & Dong-Wook Kim. (2019) Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia. Leukemia Research 76, pages 87-93.
Crossref
Nuno Cerveira, Rosa Branca Ferreira, Susana Bizarro, Cecília Correia, Lurdes Torres, Susana Lisboa, Joana Vieira, Rui Santos, Fernando Campilho, Carlos Pinho Vaz, Luís Leite, Manuel R. Teixeira & António Campos. (2018) Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report. BMC Cancer 18:1.
Crossref
Kiran Naqvi, Jorge E. Cortes, Raja Luthra, Susan O’Brien, William Wierda, Gautam Borthakur, Tapan Kadia, Guillermo Garcia-Manero, Farhad Ravandi, Mary Beth Rios, Sara Dellasala, Sherry Pierce, Elias Jabbour, Keyur Patel & Hagop Kantarjian. (2018) Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations. International Journal of Hematology 107:6, pages 689-695.
Crossref
Marina Konopleva, Alfonso Quintás Cardama, Hagop Kantarjian & Jorge Cortes. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 29 47 .
Oliver Hantschel & Oliver G. Ottmann. (2017) Allosterische KinaseinhibitorenAllosteric kinase inhibitors. Der Onkologe 23:8, pages 626-631.
Crossref
Priscila Da Silva Figueiredo Celestino Gomes, Isaure Chauvot De Beauchêne, Nicolas Panel, Sophie Lopez, Paulo De Sepulveda, Pedro Geraldo Pascutti, Eric Solary & Luba Tchertanov. (2016) Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT. PLOS ONE 11:7, pages e0160165.
Crossref
John Badger, Prerna Grover, Haibin Shi, Shoghag B. Panjarian, John R. Engen, Thomas E. Smithgall & Lee Makowski. (2016) c-Abl Tyrosine Kinase Adopts Multiple Active Conformational States in Solution. Biochemistry 55:23, pages 3251-3260.
Crossref
M S Zabriskie, C A Eide, D Yan, N A Vellore, A D Pomicter, S L Savage, B J Druker, M W Deininger & T O'Hare. (2015) Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia. Leukemia 30:6, pages 1418-1421.
Crossref
Yuming Wei, Daniel C. Poon, Rong Fei, Amy S. M. Lam, Steve C. F. Au-Yeung & Kenneth K. W. To. (2016) A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors. Scientific Reports 6:1.
Crossref
Duolan Naren, Jiahui Wu, Yuping Gong, Tianyou Yan, Ke Wang, Wenming Xu, Xi Yang, Fangfang Shi & Rui Shi. (2016) Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RI. Leukemia Research 42, pages 59-67.
Crossref
Boyang Zhao, Joseph C. Sedlak, Raja Srinivas, Pau Creixell, Justin R. Pritchard, Bruce Tidor, Douglas A. Lauffenburger & Michael T. Hemann. (2016) Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell 165:1, pages 234-246.
Crossref
Sanaz Tabarestani & Abolfazl Movafagh. (2016) New Developments in Chronic Myeloid Leukemia: Implications for Therapy. Iranian Journal of Cancer Prevention InPress:InPress.
Crossref
Isabella Haberbosch, Anahita Rafiei, Claudia Oancea, Oliver Gerhart Ottmann, Martin Ruthardt & Afsar Ali Mian. (2016) BCR: a new target in resistance mediated by BCR/ABL-315I?. Genes & Cancer 7:1-2, pages 36-46.
Crossref
Christine Kujak & Jill M. Kolesar. (2016) Treatment of chronic myelogenous leukemia. American Journal of Health-System Pharmacy 73:3, pages 113-120.
Crossref
Cho-Rong Lee, Jung-Ah Kang, Hye-Eun Kim, Yegyun Choi, Taewoo Yang & Sung-Gyoo Park. (2016) Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR - ABL mutation-independent imatinib resistance . FEBS Letters 590:3, pages 358-368.
Crossref
Hein Than, Charles Chuah & S. Tiong Ong. 2016. Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia. Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia 167 182 .
Nicolas Bosc, Berthold Wroblowski, Samia Aci-Sèche, Christophe Meyer & Pascal Bonnet. (2015) A Proteometric Analysis of Human Kinome: Insight into Discriminant Conformation-dependent Residues. ACS Chemical Biology 10:12, pages 2827-2840.
Crossref
Bushra Kaleem, Sadaf Shahab, Nuzhat Ahmed & Tahir Sultan Shamsi. (2015) Chronic Myeloid Leukemia - Prognostic Value of Mutations. Asian Pacific Journal of Cancer Prevention 16:17, pages 7415-7423.
Crossref
T P Hughes, G Saglio, A Quintás-Cardama, M J Mauro, D-W Kim, J H Lipton, M B Bradley-Garelik, J Ukropec & A Hochhaus. (2015) BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia 29:9, pages 1832-1838.
Crossref
Saadat U. Aleem, Barbara P. Craddock & W. Todd Miller. (2015) Constitutive Activity in an Ancestral Form of Abl Tyrosine Kinase. PLOS ONE 10:6, pages e0131062.
Crossref
Iris Appelmann, Cory D. Rillahan, Elisa de Stanchina, Gregory Carbonetti, Chong Chen, Scott W. Lowe & Charles J. Sherr. (2015) Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Blood 125:9, pages 1444-1451.
Crossref
Lorraine SpringuelTekla HornakovaElisabeth LosdyckFanny LambertEmilie LeroyStefan N. ConstantinescuElisabetta Flex, Marco Tartaglia, Laurent Knoops & Jean-Christophe Renauld. (2014) Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood 124:26, pages 3924-3931.
Crossref
Anna M Eiring & Michael W Deininger. (2014) Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biology 15:9.
Crossref
Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi, Nadeem A. Vellore, Johanna Estrada, Franck E. Nicolini, Hanna J. Khoury, Richard A. Larson, Marina Konopleva, Jorge E. Cortes, Hagop Kantarjian, Elias J. Jabbour, Steven M. Kornblau, Jeffrey H. Lipton, Delphine Rea, Leif Stenke, Gisela Barbany, Thoralf Lange, Juan-Carlos Hernández-Boluda, Gert J. Ossenkoppele, Richard D. Press, Charles Chuah, Stuart L. Goldberg, Meir Wetzler, Francois-Xavier Mahon, Gabriel Etienne, Michele Baccarani, Simona Soverini, Gianantonio Rosti, Philippe Rousselot, Ran Friedman, Marie Deininger, Kimberly R. Reynolds, William L. Heaton, Anna M. Eiring, Anthony D. Pomicter, Jamshid S. Khorashad, Todd W. Kelley, Riccardo Baron, Brian J. Druker, Michael W. Deininger & Thomas O’Hare. (2014) BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell 26:3, pages 428-442.
Crossref
Michele Massimino, Maria Letizia Consoli, Maria Mesuraca, Fabio Stagno, Elena Tirrò, Stefania Stella, Maria Stella Pennisi, Chiara Romano, Pietro Buffa, Heather M. Bond, Giovanni Morrone, Laura Sciacca, Francesco Di Raimondo, Livia Manzella & Paolo Vigneri. (2014) IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. Carcinogenesis 35:5, pages 1132-1143.
Crossref
Pietro Buffa, Chiara Romano, Alessandro Pandini, Michele Massimino, Elena Tirrò, Francesco Di Raimondo, Livia Manzella, Franca Fraternali & Paolo G. Vigneri. (2013) BCR‐ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein. The FASEB Journal 28:3, pages 1221-1236.
Crossref
Djamel Aggoune, Lucie Tosca, Nathalie Sorel, Marie-Laure Bonnet, Fatima Dkhissi, Gerard Tachdjian, Annelise Bennaceur-Griscelli, Jean-Claude Chomel & Ali G. Turhan. (2014) Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors. Oncoscience 1:1, pages 57-68.
Crossref
Brian G Blair, Alberto Bardelli & Ben Ho Park. (2014) Somatic alterations as the basis for resistance to targeted therapies. The Journal of Pathology 232:2, pages 244-254.
Crossref
Elias J. Jabbour, Jorge E. Cortes & Hagop M. Kantarjian. (2013) Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options. Clinical Lymphoma Myeloma and Leukemia 13:5, pages 515-529.
Crossref
Yang Kuang, K. B. Flores, Y. Zhao & R. A. Everett. (2013) Data and implication based comparison of two chronic myeloid leukemia models. Mathematical Biosciences and Engineering 10:5/6, pages 1501-1518.
Crossref
María Teresa Gómez Casares & Leticia G. León. (2013) Leucemia mieloide crónica y resistencia al tratamiento con inhibidores de la tirosincinasa: mutaciones en ABL, ¿mucho ruido y pocas nueces?. Medicina Clínica 141:3, pages 111-113.
Crossref
André Richters, Julia Ketzer, Matthäus Getlik, Christian Grütter, Ralf Schneider, Johannes M. Heuckmann, Stefanie Heynck, Martin L. Sos, Anu Gupta, Anke Unger, Carsten Schultz-Fademrecht, Roman K. Thomas, Sebastian Bauer & Daniel Rauh. (2013) Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design. Journal of Medicinal Chemistry 56:14, pages 5757-5772.
Crossref
Allan Joaquim Lamontanara, Emel Basak Gencer, Orest Kuzyk & Oliver Hantschel. (2013) Mechanisms of resistance to BCR-ABL and other kinase inhibitors. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1834:7, pages 1449-1459.
Crossref
K M Badger-Brown, L C Gillis, M L Bailey, J M Penninger & D L Barber. (2012) CBL-B is required for leukemogenesis mediated by BCR-ABL through negative regulation of bone marrow homing. Leukemia 27:5, pages 1146-1154.
Crossref
A D Whale, A Dart, M Holt, G E Jones & C M Wells. (2012) PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity. Oncogene 32:16, pages 2114-2120.
Crossref
Shoghag Panjarian, Roxana E. Iacob, Shugui Chen, Thomas E. Wales, John R. Engen & Thomas E. Smithgall. (2013) Enhanced SH3/Linker Interaction Overcomes Abl Kinase Activation by Gatekeeper and Myristic Acid Binding Pocket Mutations and Increases Sensitivity to Small Molecule Inhibitors*. Journal of Biological Chemistry 288:9, pages 6116-6129.
Crossref
A Slupianek, R Falinski, P Znojek, T Stoklosa, S Flis, V Doneddu, D Pytel, E Synowiec, J Blasiak, A Bellacosa & T Skorski. (2012) BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability. Leukemia 27:3, pages 629-634.
Crossref
Manabu KurokawaTakahiro Ito, Chih-Sheng YangChen ZhaoAndrew N. MacintyreDavid A. RizzieriJeffrey C. RathmellMichael W. Deininger, Tannishtha Reya & Sally Kornbluth. (2013) Engineering a BCR-ABL–activated caspase for the selective elimination of leukemic cells. Proceedings of the National Academy of Sciences 110:6, pages 2300-2305.
Crossref
NAN WU, TETSUYA KUROSU, GAKU OSHIKAWA, TOSHIKAGE NAGAO & OSAMU MIURA. (2013) PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells. International Journal of Oncology 42:2, pages 419-428.
Crossref
Jamshid S. KhorashadTodd W. KelleyPhilippe SzankasiClinton C. MasonSimona SoveriniLauren T. AdrianChristopher A. EideMatthew S. ZabriskieThoralf LangeJohanna C. EstradaAnthony D. PomicterAnna M. EiringIra L. KraftDavid J. AndersonZhimin GuMary Alikian, Alistair G. Reid, Letizia Foroni, David Marin, Brian J. DrukerThomas O'Hare & Michael W. Deininger. (2013) BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships. Blood 121:3, pages 489-498.
Crossref
Shan Yang, Angela Proctor, Lauren L. Cline, Kaiulani M. Houston, Marcey L. Waters & Nancy L. Allbritton. (2013) β-Turn sequences promote stability of peptide substrates for kinases within the cytosolic environment. The Analyst 138:15, pages 4305.
Crossref
Seonyang Park, Youngil Koh, Seung-Hyun Jung & Yeun-Jun Chung. 2013. Array Comparative Genomic Hybridization. Array Comparative Genomic Hybridization 55 68 .
Elisa Zucca, Emmanuele Crespan, Federica Bertoletti, Miroslava Kissova & Giovanni Maga. 2013. Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy. Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy 163 186 .
Alfonso Quintás Cardama, Hagop Kantarjian & Jorge Cortes. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 29 44 .
M. Gniot, E. M. Wasilewska & K. Lewandowski. (2012) K356dup - an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia . International Journal of Laboratory Hematology 34:6, pages e3-e6.
Crossref
Georg E Winter, Uwe Rix, Scott M Carlson, Karoline V Gleixner, Florian Grebien, Manuela Gridling, André C Müller, Florian P Breitwieser, Martin Bilban, Jacques Colinge, Peter Valent, Keiryn L Bennett, Forest M White & Giulio Superti-Furga. (2012) Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nature Chemical Biology 8:11, pages 905-912.
Crossref
Ann Cai, Derin B. Keskin, David S. DeLuca, Anselmo Alonso, Wandi Zhang, Guang Lan Zhang, Naa Norkor Hammond, Valentina Nardi, Richard M. Stone, Donna Neuberg, John Sidney, Vladimir Brusic & Catherine J. Wu. (2012) Mutated BCR-ABL Generates Immunogenic T-cell Epitopes in CML Patients . Clinical Cancer Research 18:20, pages 5761-5772.
Crossref
Simona SoveriniGiovanni Martinelli, Gianantonio Rosti, Ilaria Iacobucci & Michele Baccarani. (2012) Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis. Pharmacogenomics 13:11, pages 1271-1284.
Crossref
H Pfeifer, T Lange, S Wystub, B Wassmann, J Maier, A Binckebanck, A Giagounidis, M Stelljes, M Schmalzing, U Dührsen, L Wunderle, H Serve, P Brück, A Schmidt, D Hoelzer & O G Ottmann. (2012) Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia 26:7, pages 1475-1481.
Crossref
Tomasz Skorski. (2012) Genetic Mechanisms of Chronic Myeloid Leukemia Blastic Transformation. Current Hematologic Malignancy Reports 7:2, pages 87-93.
Crossref
Wanwisa Wongboonma, Wanna Thongnoppakhun & Chirayu U. Auewarakul. (2012) BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients. Experimental and Molecular Pathology 92:2, pages 259-265.
Crossref
Oliver Weigert, Andrew A. Lane, Liat Bird, Nadja Kopp, Bjoern Chapuy, Diederik van Bodegom, Angela V. Toms, Sachie Marubayashi, Amanda L. Christie, Michael McKeown, Ronald M. Paranal, James E. Bradner, Akinori Yoda, Christoph Gaul, Eric Vangrevelinghe, Vincent Romanet, Masato Murakami, Ralph Tiedt, Nicolas Ebel, Emeline Evrot, Alain De Pover, Catherine H. Régnier, Dirk Erdmann, Francesco Hofmann, Michael J. Eck, Stephen E. Sallan, Ross L. Levine, Andrew L. Kung, Fabienne Baffert, Thomas Radimerski & David M. Weinstock. (2012) Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. Journal of Experimental Medicine 209:2, pages 259-273.
Crossref
Thomas Ernst & Andreas Hochhaus. (2012) Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression. Seminars in Oncology 39:1, pages 58-66.
Crossref
Nicolai Härtel, Thomas Klag, Benjamin Hanfstein, Martin C. Mueller, Thomas Schenk, Philipp Erben, Andreas Hochhaus & Paul La Rosée. (2011) Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. Journal of Cancer Research and Clinical Oncology 138:2, pages 203-212.
Crossref
Angela Proctor, Qunzhao Wang, David S. Lawrence & Nancy L. Allbritton. (2012) Metabolism of peptide reporters in cell lysates and single cells. The Analyst 137:13, pages 3028.
Crossref
Wen Chun Juan & S. Tiong Ong. 2012. Protein Phosphorylation in Health and Disease. Protein Phosphorylation in Health and Disease 107 142 .
Jean-Claude Chomel, Nathalie Sorel & Ali G. Turhan. 2012. Stem Cells and Cancer Stem Cells, Volume 8. Stem Cells and Cancer Stem Cells, Volume 8 305 315 .
Andrew Coveler & Vivian G. Oehler. 2012. Leukemia and Related Disorders. Leukemia and Related Disorders 97 147 .
Benjamin Werner, David Lutz, Tim H. Brümmendorf, Arne Traulsen & Stefan Balabanov. (2011) Dynamics of Resistance Development to Imatinib under Increasing Selection Pressure: A Combination of Mathematical Models and In Vitro Data. PLoS ONE 6:12, pages e28955.
Crossref
Marc Billaud & Massimo Santoro. (2011) Is Co-option a Prevailing Mechanism during Cancer Progression?. Cancer Research 71:21, pages 6572-6575.
Crossref
Jamshid S. Khorashad & Michael W.N. Deininger. (2011) Selection of Therapy: Rational Decisions Based on Molecular Events. Hematology/Oncology Clinics of North America 25:5, pages 1009-1023.
Crossref
Thomas Ernst, Paul La Rosée, Martin C. Müller & Andreas Hochhaus. (2011) BCR-ABL Mutations in Chronic Myeloid Leukemia. Hematology/Oncology Clinics of North America 25:5, pages 997-1008.
Crossref
Marta Albajar, M. Teresa Gómez-Casares, Javier Llorca, Itsaso Mauleon, Jose P. Vaqué, Juan C. Acosta, Arancha Bermúdez, Nicholas Donato, M. Dolores Delgado & Javier León. (2011) MYC in Chronic Myeloid Leukemia: Induction of Aberrant DNA Synthesis and Association with Poor Response to Imatinib. Molecular Cancer Research 9:5, pages 564-576.
Crossref
Elias Jabbour, Susan Branford, Giuseppe Saglio, Dan Jones, Jorge E. Cortes & Hagop M. Kantarjian. (2011) Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 117:9, pages 1800-1811.
Crossref
Nidal BoulosHeather L. MulderChristopher R. CalabreseJeffrey B. MorrisonJerold E. RehgMary V. Relling, Charles J. Sherr & Richard T. Williams. (2011) Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood 117:13, pages 3585-3595.
Crossref
Alexis B. Cortot & Pasi A. Jänne. 2011. Targeted Therapies. Targeted Therapies 1 31 .
S. Schenone, O. Bruno, M. Radi & M. Botta. (2011) New insights into small-molecule inhibitors of Bcr-Abl. Medicinal Research Reviews 31:1, pages 1-41.
Crossref
Olga Sala‐Torra & Jerald P. Radich. 2010. Leukemias: Principles and Practice of Therapy. Leukemias: Principles and Practice of Therapy 228 243 .
D Sears, P Luong, M Yuan, G Nteliopoulos, Y K S Man, J V Melo & S Basu. (2010) Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia. Cell Death & Disease 1:11, pages e93-e93.
Crossref
Zhuang Zuo, Dan Jones, Hui Yao, Deborah A Thomas, Susan O'Brien, Farhad Ravandi, Hagop M Kantarjian, Lynne V Abruzzo, L Jeffrey Medeiros, Su S Chen & Rajyalakshmi Luthra. (2010) A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Modern Pathology 23:11, pages 1524-1534.
Crossref
Daniel W. SherbenouOliver HantschelInes KaupeStephanie WillisThomas BummLalita P. TuragaThoralf LangeKim-Hien DaoRichard D. Press, Brian J. Druker, Giulio Superti-FurgaMichael W. Deininger. (2010) BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 116:17, pages 3278-3285.
Crossref
Paul La Rosée & Michael W. Deininger. (2010) Resistance to Imatinib: Mutations and Beyond. Seminars in Hematology 47:4, pages 335-343.
Crossref
Nikolai Velev, Jorge Cortes, Richard Champlin, Dan Jones, Gabriela Rondon, Sergio Giralt, Gautam Borthakur, Hagop M. Kantarjian & Marcos De Lima. (2010) Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 116:15, pages 3631-3637.
Crossref
Danilo Perrotti, Catriona Jamieson, John Goldman & Tomasz Skorski. (2010) Chronic myeloid leukemia: mechanisms of blastic transformation. Journal of Clinical Investigation 120:7, pages 2254-2264.
Crossref
Elizabeth Vogel Taylor, Jennifer A. Fortune & Catherine L. Drennan. (2010) A research-inspired laboratory sequence investigating acquired drug resistance. Biochemistry and Molecular Biology Education 38:4, pages 247-252.
Crossref
M P Albero, J M Vaquer, E J Andreu, J J Villanueva, L Franch, C Ivorra, E Poch, X Agirre, F Prosper & I Pérez-Roger. (2010) Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells. Oncogene 29:22, pages 3276-3286.
Crossref
S A Bright, A M McElligott, J W O'Connell, L O'Connor, P Carroll, G Campiani, M W Deininger, E Conneally, M Lawler, D C Williams & D M Zisterer. (2010) Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. British Journal of Cancer 102:10, pages 1474-1482.
Crossref
Andrea Hoelbl, Christian Schuster, Boris Kovacic, Bingmei Zhu, Mark Wickre, Maria A. Hoelzl, Sabine Fajmann, Florian Grebien, Wolfgang Warsch, Gabriele Stengl, Lothar Hennighausen, Valeria Poli, Hartmut Beug, Richard Moriggl & Veronika Sexl. (2010) Stat5 is indispensable for the maintenance of bcr/abl ‐positive leukaemia . EMBO Molecular Medicine 2:3, pages 98-110.
Crossref
Susan Branford, Junia V. Melo & Timothy P. Hughes. (2009) Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood 114:27, pages 5426-5435.
Crossref
Dragana Milojkovic & Jane Apperley. (2009) Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. Clinical Cancer Research 15:24, pages 7519-7527.
Crossref
Xiaomin Zheng, Claudia Oancea, Reinhard Henschler, Malcolm A. S. Moore & Martin Ruthardt. (2009) Reciprocal t(9;22) ABL/BCR Fusion Proteins: Leukemogenic Potential and Effects on B Cell Commitment. PLoS ONE 4:10, pages e7661.
Crossref
Timothy P. Hughes & Susan Branford. (2009) Measuring Minimal Residual Disease in Chronic Myeloid Leukemia: Fluorescence In Situ Hybridization and Polymerase Chain Reaction. Clinical Lymphoma and Myeloma 9, pages S266-S271.
Crossref
A A Mian, M Schüll, Z Zhao, C Oancea, A Hundertmark, T Beissert, O G Ottmann & M Ruthardt. (2009) The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia 23:9, pages 1614-1621.
Crossref
Lihui Lu, Arup K. Ghose, Matthew R. Quail, Mark S. Albom, John T. Durkin, Beverly P. Holskin, Thelma S. Angeles, Sheryl L. Meyer, Bruce A. Ruggeri & Mangeng Cheng. (2009) ALK Mutants in the Kinase Domain Exhibit Altered Kinase Activity and Differential Sensitivity to Small Molecule ALK Inhibitors. Biochemistry 48:16, pages 3600-3609.
Crossref
Alfonso Quintás-CardamaHagop M. KantarjianJorge E. Cortes. (2009) Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia. Cancer Control 16:2, pages 122-131.
Crossref
Dushyant Verma, Carmen Fava, Hagop Kantarjian & Jorge Cortes. (2009) Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. American Journal of Hematology 84:4, pages 256-257.
Crossref
Alfonso Quintás-Cardama & Jorge Cortes. (2009) Molecular biology of bcr-abl1–positive chronic myeloid leukemia. Blood 113:8, pages 1619-1630.
Crossref
Roxana E. Iacob, Teodora Pene-DumitrescuJianming Zhang, Nathanael S. Gray, Thomas E. SmithgallJohn R. Engen. (2009) Conformational disturbance in Abl kinase upon mutation and deregulation. Proceedings of the National Academy of Sciences 106:5, pages 1386-1391.
Crossref
Rina Barouch-Bentov, Jianwei Che, Christian C. Lee, Yating Yang, Ann Herman, Yong Jia, Anastasia Velentza, James Watson, Luise Sternberg, Sunjun Kim, Niusha Ziaee, Andrew Miller, Carie Jackson, Manabu Fujimoto, Mike Young, Serge Batalov, Yi Liu, Markus Warmuth, Tim Wiltshire, Michael P. Cooke & Karsten Sauer. (2009) A Conserved Salt Bridge in the G Loop of Multiple Protein Kinases Is Important for Catalysis and for In Vivo Lyn Function. Molecular Cell 33:1, pages 43-52.
Crossref
Wan-Seok Kim, Dongho Kim, Dong-Wook Kim, Il-Young Kweon, Soo-Hyun Kim, Hyun-Gyung Goh, Sa-Hee Park & Jeong Lee. (2009) Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. Hematological Oncology, pages n/a-n/a.
Crossref
Shundong Cang & Delong Liu. (2008) P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. Journal of Hematology & Oncology 1:1.
Crossref
Yelena Krijanovski, Nicholas Donato, Hanshi Sun, Feng Meng, Alfonso Quintás-Cardama, Jorge E. Cortés & Moshe Talpaz. (2008) Dasatinib Resistance in Patients with Chronic Myelogenous Leukemia: Identification of a Novel bcr-abl Kinase Domain Mutation. Clinical Leukemia 2:4, pages 267-271.
Crossref
Xiaoqing Cao, Keith Q. Tanis, Anthony J. Koleske & John Colicelli. (2008) Enhancement of ABL Kinase Catalytic Efficiency by a Direct Binding Regulator Is Independent of Other Regulatory Mechanisms. Journal of Biological Chemistry 283:46, pages 31401-31407.
Crossref
N C P Cross, G Q Daley, A R Green, T P Hughes, C Jamieson, P Manley, T Mughal, D Perrotti, J Radich, R Skoda, S Soverini, W Vainchenker, S Verstovsek, J-L Villeval & J M Goldman. (2008) BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia 22:11, pages 1975-1989.
Crossref
Mohammad Azam, Markus A Seeliger, Nathanael S Gray, John Kuriyan & George Q Daley. (2008) Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nature Structural & Molecular Biology 15:10, pages 1109-1118.
Crossref
David J L Joske. (2008) Chronic myeloid leukaemia: the evolution of gene‐targeted therapy. Medical Journal of Australia 189:5, pages 277-282.
Crossref
Kimberly Cramer, Margaret Nieborowska-Skorska, Mateusz Koptyra, Artur Slupianek, Emir Tyrone P. Penserga, Connie J. Eaves, Walter Aulitzky & Tomasz Skorski. (2008) BCR/ABL and Other Kinases from Chronic Myeloproliferative Disorders Stimulate Single-Strand Annealing, an Unfaithful DNA Double-Strand Break Repair. Cancer Research 68:17, pages 6884-6888.
Crossref
Peter Valent. (2008) Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. British Journal of Haematology 142:3, pages 361-378.
Crossref
M MacPartlin, A M Smith, B J Druker, L A Honigberg & M W Deininger. (2008) Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 22:7, pages 1354-1360.
Crossref
Tim Beissert, Alena Hundertmark, Velina Kaburova, Lorena Travaglini, Afsar A. Mian, Clara Nervi & Martin Ruthardt. (2008) Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. International Journal of Cancer 122:12, pages 2744-2752.
Crossref
Thomas O'Hare, Christopher A. Eide, Jeffrey W. Tyner, Amie S. Corbin, Matthew J. Wong, Sean Buchanan, Kevin Holme, Katayoun A. Jessen, Crystal Tang, Hal A. Lewis, Richard D. Romero, Stephen K. Burley & Michael W. Deininger. (2008) SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinib . Proceedings of the National Academy of Sciences 105:14, pages 5507-5512.
Crossref
Efstratios Katsoulidis, Antonella Sassano, Beata Majchrzak-Kita, Nathalie Carayol, Patrick Yoon, Alison Jordan, Brian J. Druker, Eleanor N. Fish & Leonidas C. Platanias. (2008) Suppression of Interferon (IFN)-inducible Genes and IFN-mediated Functional Responses in BCR-ABL-expressing Cells. Journal of Biological Chemistry 283:16, pages 10793-10803.
Crossref
J Liu, S Joha, T Idziorek, S Corm, D Hetuin, N Philippe, C Preudhomme & B Quesnel. (2008) BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia 22:4, pages 791-799.
Crossref
Paul La Rosée & Andreas Hochhaus. (2008) Resistance to imatinib in chronic myelogenous leukemia: Mechanisms and clinical implications. Current Hematologic Malignancy Reports 3:2, pages 72-79.
Crossref
Giuseppe Saglio, Stefano Ulisciani, Milena Fava, Enrico Gottardi & Daniela Cilloni. (2008) Molecular monitoring in patients with chronic myelogenous leukemia. Current Hematologic Malignancy Reports 3:2, pages 65-71.
Crossref
Nathalie Carayol, Efstratios Katsoulidis, Antonella Sassano, Jessica K. Altman, Brian J. Druker & Leonidas C. Platanias. (2008) Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway. Journal of Biological Chemistry 283:13, pages 8601-8610.
Crossref
Jiefei Tong, Paul Taylor, Eleonora Jovceva, Jonathan R. St-Germain, Lily L. Jin, Ana Nikolic, Xiaoping Gu, Zhi Hua Li, Suzanne Trudel & Michael F. Moran. (2008) Tandem Immunoprecipitation of Phosphotyrosine-Mass Spectrometry (TIPY-MS) Indicates C19ORF19 Becomes Tyrosine-Phosphorylated and Associated with Activated Epidermal Growth Factor Receptor. Journal of Proteome Research 7:3, pages 1067-1077.
Crossref
Jamshid S. Khorashad, Dragana Milojkovic, Puja Mehta, Mona Anand, Sara Ghorashian, Alistair G. Reid, Valeria De Melo, Anna Babb, Hugues de Lavallade, Eduardo Olavarria, David Marin, John M. Goldman, Jane F. Apperley & Jaspal S. Kaeda. (2008) In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 111:4, pages 2378-2381.
Crossref
Jeffrey A Engelman & Jeffrey Settleman. (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Current Opinion in Genetics & Development 18:1, pages 73-79.
Crossref
Mark R. Litzow. 2009. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response 127 150 .
Yesid Alvarado & Jorge E. Cortés. (2007) Emerging Role of Aurora Kinase Inhibitors in Chronic Myeloid Leukemia. Clinical Leukemia 1:6, pages 325-330.
Crossref
Jane F Apperley. (2007) Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. The Lancet Oncology 8:11, pages 1018-1029.
Crossref
Hugues de Lavallade, Jamshid S. Khorashad, Howard P. Davis, Dragana Milojkovic, Jaspal S. Kaeda, John M. Goldman, Jane F. Apperley & David Marin. (2007) Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 110:7, pages 2779-2780.
Crossref
Thomas O'Hare, Christopher A. Eide & Michael W. N. Deininger. (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:7, pages 2242-2249.
Crossref
Neil P. Shah, Brian J. Skaggs, Susan Branford, Timothy P. Hughes, John M. Nicoll, Ronald L. Paquette & Charles L. Sawyers. (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. Journal of Clinical Investigation 117:9, pages 2562-2569.
Crossref
Li-Rong Yu, Haleem J. Issaq & Timothy D. Veenstra. (2007) Phosphoproteomics for the discovery of kinases as cancer biomarkers and drug targets. PROTEOMICS – CLINICAL APPLICATIONS 1:9, pages 1042-1057.
Crossref
Daniel W. Sherbenou & Brian J. Druker. (2007) Applying the discovery of the Philadelphia chromosome. Journal of Clinical Investigation 117:8, pages 2067-2074.
Crossref
Andreas Burchert. (2007) Roots of imatinib resistance: A question of self-renewal?. Drug Resistance Updates 10:4-5, pages 152-161.
Crossref
Timothy Hughes & Susan Branford. (2007) Ph+ ALL: resistance seeds sown early. Blood 110:2, pages 472-472.
Crossref
Heike PfeiferBarbara WassmannAnna PavlovaLydia WunderleJohannes OldenburgAnja BinckebanckThoralf Lange, Andreas Hochhaus, Silvia WystubPatrick BrückDieter HoelzerOliver G. Ottmann. (2007) Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 110:2, pages 727-734.
Crossref
Tariq I. Mughal. (2007) Do Kinase Domain Mutations in Philadelphia Chromosome–Positive Leukemias Really Matter?. Clinical Leukemia 1:4, pages 207.
Crossref
Junia V. Melo & David J. Barnes. (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nature Reviews Cancer 7:6, pages 441-453.
Crossref
Ellen Weisberg, Paul W. Manley, Sandra W. Cowan-Jacob, Andreas Hochhaus & James D. Griffin. (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature Reviews Cancer 7:5, pages 345-356.
Crossref
Thomas O'Hare, Christopher A. Eide & Michael W. Deininger. (2007) Bcr-Abl Kinase Domain Mutations and the Unsettled Problem of Bcr-AblT315I: Looking into the Future of Controlling Drug Resistance in Chronic Myeloid Leukemia. Clinical Lymphoma and Myeloma 7, pages S120-S130.
Crossref
Ronan Swords, Yesid Alvarado & Francis Giles. (2007) Novel Abl Kinase Inhibitors in Chronic Myeloid Leukemia in Blastic Phase and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma and Myeloma 7, pages S113-S119.
Crossref
Susan Branford. (2007) Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice. Hematology 2007:1, pages 376-383.
Crossref
Brian J. SkaggsMercedes E. GorreAnn RyvkinMichael R. BurgessYongming XieYun HanEvangelia KomisopoulouLauren M. BrownJoseph A. LooElliot M. Landaw, Charles L. Sawyers & Thomas G. Graeber. (2006) Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proceedings of the National Academy of Sciences 103:51, pages 19466-19471.
Crossref
Brian J. Druker, François Guilhot, Stephen G. O'Brien, Insa Gathmann, Hagop Kantarjian, Norbert Gattermann, Michael W.N. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice L. Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John Shepherd, Giuseppe Saglio, Alois Gratwohl, Johan L. Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak & Richard A. Larson. (2006) Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. New England Journal of Medicine 355:23, pages 2408-2417.
Crossref
Tariq I. Mughal & John M. Goldman. (2006) A Perspective on the Molecular Evolution of Chronic Myeloid Leukemia from Chronic Phase to Blast Transformation. Clinical Leukemia 1:2, pages 101-107.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.